MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
| Revenue (TTM) | $360.78M |
| Gross Profit (TTM) | $272.87M |
| EBITDA | $35.32M |
| Operating Margin | -3.31% |
| Return on Equity | 0.00% |
| Return on Assets | 2.03% |
| Revenue/Share (TTM) | $1.31 |
| Book Value | $-0.19 |
| Price-to-Book | 187.85 |
| Price-to-Sales (TTM) | 3.64 |
| EV/Revenue | 4.426 |
| EV/EBITDA | 57.86 |
| Quarterly Earnings Growth (YoY) | -34.90% |
| Quarterly Revenue Growth (YoY) | 15.10% |
| Shares Outstanding | $308.95M |
| Float | $303.07M |
| % Insiders | 1.55% |
| % Institutions | 59.49% |
Volatility is currently expanding
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as a durable growth inflection, targeting a concentrated 360,000-patient U.S. base and 30,000 annual inflow, with an efficient commercial strategy. MNKD estimates a 23–37% pediatric market share, translating to a $300–500 million revenue opportunity, with gradual adoption expected to accelerate meaningfully by 4Q26 and into 2027.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.
The U.S. Food and Drug Administration has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, offering patients under 18 years of age a needle-free treatment option, the company said on Friday.
MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD's Tyvaso DPI royalties, intensifying competitive risks and highlighting MNKD's junior partner status. Pipeline prospects, including MNKD-201 and ralinepag DPI, offer potential but face significant clinical, commercial, and competitive hurdles.
